{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T08:27:57Z","timestamp":1781598477266,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jval.2020.10.006","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T22:17:19Z","timestamp":1605824239000},"page":"268-273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products"],"prefix":"10.1016","volume":"24","author":[{"given":"Sandra M.","family":"Sirrs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Francoise","family":"Arthus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Bichet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Rockman-Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaye","family":"LeMoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal F.","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry D.","family":"Lynd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Wasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2020.10.006_bib1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jval.2018.01.008","article-title":"Evaluating and valuing drugs for rare conditions: no easy answers","volume":"21","author":"Ollendorf","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.10.006_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-016-0551-7","article-title":"Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients\u2019 health needs?","volume":"12","author":"Rodriguez-Monguio","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jval.2020.10.006_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13023-017-0601-9","article-title":"Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)","volume":"12","author":"Annemans","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jval.2020.10.006_bib4","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.healthpol.2017.09.005","article-title":"A\u00a0review of international coverage and pricing strategies for personalized medicine and orphan drugs","volume":"121","author":"Degtiar","year":"2017","journal-title":"Health Policy"},{"key":"10.1016\/j.jval.2020.10.006_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13023-017-0611-7","article-title":"Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost","volume":"12","author":"Rawson","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jval.2020.10.006_bib6","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/pds.4332","article-title":"Registries supporting new drug applications","volume":"26","author":"Jonker","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jval.2020.10.006_bib7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ymgme.2009.11.001","article-title":"Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative","volume":"99","author":"Sirrs","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jval.2020.10.006_bib8","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s40264-019-00848-9","article-title":"Patient registries: an underused resource for medicines evaluation","author":"McGettigan","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.jval.2020.10.006_bib9","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/jmg.28.4.232","article-title":"Fabry disease in a large Nova Scotia kindred: carrier detection using leucocyte alpha-galactosidase activity and an NcoI polymorphism detected by an alpha-galactosidase cDNA clone","volume":"28","author":"Kirkilionis","year":"1991","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.jval.2020.10.006_bib12","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(15)00827-2","article-title":"Post-authorisation assessment of orphan drugs","volume":"386","author":"Hollak","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2020.10.006_bib13","author":"Sirrs"},{"key":"10.1016\/j.jval.2020.10.006_bib14","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease: overall effects of agalsidase alfa treatment","volume":"34","author":"Beck","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jval.2020.10.006_bib15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.jval.2020.10.006_bib16","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"24","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jval.2020.10.006_bib17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry Disease Initiative","volume":"111","author":"Sirrs","year":"2014","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jval.2020.10.006_bib18","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jval.2020.10.006_bib19","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jval.2020.10.006_bib20","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","article-title":"Cardiovascular events in patients with Fabry disease: natural history data from the Fabry Registry","volume":"57","author":"Patel","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jval.2020.10.006_bib21","first-page":"540","article-title":"Patient registries of acute coronary syndrome: assessing or biasing the clinical real world data?","volume":"2","author":"Ferreira-Gonz\u00e1lez","year":"2009","journal-title":"Circ Cardiovasc Qual"},{"issue":"8","key":"10.1016\/j.jval.2020.10.006_bib22","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1210\/jc.2018-02413","article-title":"Letter to the editor: efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: a phase 2 open-label study","volume":"104","author":"Rockman-Greenberg","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jval.2020.10.006_bib23","first-page":"545","article-title":"An internal standard for verifying the accuracy of serious adverse event reporting: the example of an acupuncture study of 190 924 patients","volume":"9","author":"Endres","year":"2004","journal-title":"Eur J Med Res"},{"issue":"6","key":"10.1016\/j.jval.2020.10.006_bib24","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jval.2016.04.009","article-title":"Increasing patient involvement in drug development","volume":"19","author":"Lowe","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.10.006_bib25","author":"Chappell"},{"key":"10.1016\/j.jval.2020.10.006_bib26","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/pds.4449","article-title":"Imposed registries within the European postmarketing surveillance system: extended analysis and lessons learned for regulators","volume":"27","author":"Pacurariu","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jval.2020.10.006_bib27","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.bcmd.2017.01.013","article-title":"Design of a framework for the deployment of collaborative independent rare disease-centric registries: Gaucher disease registry model","volume":"68","author":"Bellgard","year":"2018","journal-title":"Blood Cell Mol Dis"},{"key":"10.1016\/j.jval.2020.10.006_bib29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","article-title":"Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study","volume":"55","author":"Arends","year":"2018","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.jval.2020.10.006_bib30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J\u00a0Biomed Inform"},{"key":"10.1016\/j.jval.2020.10.006_bib31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13023-020-01358-z","article-title":"Evaluation of the quality of clinical data collection for a pan-Canadian cohort of children affected by inherited metabolic diseases: lessons learned from the Canadian Inherited Metabolic Diseases Research Network","volume":"15","author":"Tingley","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jval.2020.10.006_bib33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13023-019-1091-8","article-title":"Research activity and capability in the European reference network MetabERN","volume":"14","author":"Heard","year":"2019","journal-title":"Orphanet J Rare Dis"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520344491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520344491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:23:22Z","timestamp":1761096202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301520344491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1098301520344491"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.10.006","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}